Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketmoversinsider.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketMoversInsider.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent ICPT Stock Price: $13.48
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
Geoff Meacham analyst at Bank of America Securities reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Sell rating and has set ICPT's stock price target at $ 14.
TipRanks.com reports that Intercept Pharma currently has 11 analysts offering 12-month price targets on ICPT and the consensus is a Moderate Buy rating with an average stock price target of $24.00. The most recent ICPT stock price we have is $13.48 and we are not making any ICPT forecasts at this time.
In addition, TradingView issued a Strong Sell rating for ICPT over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ICPT, please click here >>
Rocket Pharmaceuticals, RCKT
Recent RCKT Stock Price: $15.5
Summary: Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
Steven Seedhouse analyst at Raymond James reiterates coverage on Rocket Pharmaceuticals (RCKT) stock in the energy sector with a Buy rating and has set RCKT's stock price target at $ 34.
TipRanks.com reports that Rocket Pharmaceuticals currently has 9 analysts offering 12-month price targets on RCKT and the consensus is a Strong Buy rating with an average stock price target of $57.71. The most recent RCKT stock price we have is $15.5 and we are not making any RCKT forecasts at this time.
In addition, TradingView issued a Buy rating for RCKT over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RCKT. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RCKT, please click here >>
Axcella Health, AXLA
Recent AXLA Stock Price: $1.93
Summary: Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical stage. Axcella Health Inc. is based in Cambridge, Massachusetts.
Ed Arce analyst at H.C. Wainwright reiterates coverage on Axcella Health (AXLA) stock in the energy sector with a Buy rating and has set AXLA's stock price target at $ 10.
TipRanks.com reports that Axcella Health currently has 5 analysts offering 12-month price targets on AXLA and the consensus is a Strong Buy rating with an average stock price target of $8.50. The most recent AXLA stock price we have is $1.93 and we are not making any AXLA forecasts at this time.
In addition, TradingView issued a Neutral rating for AXLA over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AXLA. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AXLA, please click here >>
Cytokinetics, CYTK
Recent CYTK Stock Price: $51.11
Summary: Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Jason Butler analyst at JMP Securities reiterates coverage on Cytokinetics (CYTK) stock in the energy sector with a Buy rating and has set CYTK's stock price target at $ 82.
TipRanks.com reports that Cytokinetics currently has 9 analysts offering 12-month price targets on CYTK and the consensus is a Strong Buy rating with an average stock price target of $68.11. The most recent CYTK stock price we have is $51.11 and we are not making any CYTK forecasts at this time.
In addition, TradingView issued a Buy rating for CYTK over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYTK. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CYTK, please click here >>
Axsome Therapeutics, AXSM
Recent AXSM Stock Price: $45.33
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
Ram Selvaraju analyst at H.C. Wainwright reiterates coverage on Axsome Therapeutics (AXSM) stock in the energy sector with a Buy rating and has set AXSM's stock price target at $ 210.
TipRanks.com reports that Axsome Therapeutics currently has 9 analysts offering 12-month price targets on AXSM and the consensus is a Strong Buy rating with an average stock price target of $96.00. The most recent AXSM stock price we have is $45.33 and we are not making any AXSM forecasts at this time.
In addition, TradingView issued a Sell rating for AXSM over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AXSM. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AXSM, please click here >>
The editors at marketmoversinsider.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketMoversInsider.com is for serious traders.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================